Arcus Biosciences’ Post

A cystic fibrosis diagnosis once meant a life expectancy only through early adulthood. However, thanks to the development of therapeutics that target the CFTR proteins responsible for this disease, CF patients can now expect to live significantly longer than before. In a recent article exploring treatment options for #CF, our very own trial manager with extensive experience in this space, Nadia Shive, shared her insights on these vital therapies, challenges in cystic fibrosis clinical trials, and more in Labiotech.eu. Read the full article here: https://lnkd.in/eTnC5VEU #respiratoryhealth #cysticfibrosis #cysticfibrosismarket #clinicaltrials

Introducing our In Focus, sponsored by Sino Biological, Inc. on cytokines in immunotherapy! This video introduces cytokines, including how they regulate the immune system, their use as immunotherapies and the challenges associated with their clinical application. >>> https://hubs.ly/Q02HcrZf0

🚀 Zumutor Biologics: Pioneering #Antibody Therapy for #SolidTumors 🧬 First Patient Dosed in #Phase1 Clinical Trial Zumutor Biologics has started its Phase 1 clinical trial for #ZM008, an innovative #antiLLT1 antibody. 🧪 Groundbreaking Science ZM008 is a fully #humanIgG1 monoclonal antibody. It targets LLT1 (CLEC2D), disrupting the interaction between #NKcells and #TumorCells. This activation transforms “cold” tumors into “hot” tumors, enhancing immune response. 💡 Clinical Trial Design - Open-label, multicenter Phase 1 trial. - Evaluates ZM008 alone and with pembrolizumab. - Focuses on advanced solid tumors with no standard options. - Includes cancers like NSCLC, TNBC, HNSCC, prostate cancer, CRC, HGSOC. 🔬 Key Assessments - Safety and #pharmacokinetics. - Maximum tolerated #dose. - #Pharmacodynamic biomarkers. - Initial #antitumor activity. - Phase 2 dose recommendation. 🌐 Patient Enrollment - Adults 18+ with advanced metastatic solid tumors. - Adequate hematologic, renal, and hepatic functions required. - Excludes patients with history of auto-immune reactions. 🔎 Scientific Insights “Activation of immune pathways by targeting this novel mechanism with ZM008 will be a viable option for patients to fight advanced solid cancers.” – Maloy Ghosh, CSO, Zumutor Biologics. 📊 Exciting Potential “We are eager to see this novel monoclonal antibody advance through clinical trials and hope it will one day be available for these patients in need.” – Kavitha Iyer Rodrigues, CEO, Zumutor Biologics. 👏 Developing targeted antibody therapy is incredibly challenging, requiring precision and innovation. Kudos to Zumutor Biologics for achieving this significant milestone. #ClinicalTrials #Oncology #Biotech #ZumutorBiologics #Innovation #Healthcare

How to recognize metastatic HER2 breast cancer long term survivors? Very hot topic that we will try to answer with UCBG and UNICANCER, thanks to 2023 PHRC grant from French Ministry of health and Natera partnership.

Understanding the patient's unique biological makeup is only possible through accurate laboratory diagnostic testing. It becomes the compass, pointing us in the right direction for each individual's treatment plan. No longer are we guessing, but we're strategizing with data-driven insights. Moreover, these tests are also the backbone of clinical trials. They help verify the efficacy of new drugs and treatment modalities, making sure new solutions are safe and effective. No matter the complexity of the disease, from the common cold to cancer, diagnostic testing is our best tool for gaining an understanding of the human body's response, helping us tailor care to the individual and advance medicine as a whole. It's through this approach that we can continue transforming patient care for the better. #Diagnostictesting! Is it truly recognize as a crucial link in the chain of finding the right treatment?

🌟 NEW EPISODE ALERT 🌟 Dive deep into the world of Idiopathic Pulmonary Fibrosis (IPF) with Dr. Victor Thannickal on our latest episode of BIO from the BAYOU. 🎙️ Learn about the symptoms, progression, and the groundbreaking drug therapies being developed to combat this devastating lung disease. 🔍 Highlights: • Understanding IPF fundamentals • Impact on patient lives • Innovative therapies from Dr. Thannickal’s lab • Latest research advancements 📲 Listen now and stay ahead in biotech developments! #Biotech #HealthcareInnovation #IPF #LungDisease #PharmaceuticalResearch ➡️ Listen to Episode 36 Now (link in comments)

🌟 Research Update! 🌟 The #QUILT trial analyzed the effects of the IL-15RαFc superagonist #nogapendekin alfa #inbakicept plus #BCG on patients with BCG-unresponsive #NMIBC. Learn more:

LinkedIn network, looking for your help from those that market therapeutics in rare diseases. What are the best conferences you have participated as an exhibitor? Looking for all specialties. TIA for your input! Some I have participated in are ASH, Kidney Week, AAD, and Fall Clinical. #pharmamarketing #conference2024 #raredisease #healthcareanalytics

Really excited to share our recent publication at #ScientificReports on Multiplexing Snakebite Diagnostics 🐍 The VenomAid Diagnostics team has successfully developed a multiplexed lateral flow assay for detecting Brazilian Bothrops and Lachesis venoms in human samples. 🧪 Our diagnostic test, based on monoclonal antibodies, can distinguish between Bothrops and Lachesis spp., addressing challenges in syndromic approaches for snakebite envenomation diagnosis. The assay is also optimized for various biological samples and avoids false positives. 🩸 Results, both qualitative and (semi)quantitative, can be easily interpreted with the naked eye or a smartphone with a 3D-printed attachment. ⏱ With a precise diagnosis, healthcare professionals can administer targeted and timely treatment for snakebite envenomation. This work could potentially improve patient outcomes and reduce the risk of complications associated with delayed or inappropriate interventions. Impressively co-led by Cecilie Knudsen, Selma Blom Belfakir, Pelle Degnegaard Knudsen, and Gina Ross, joined by co-authors Søren Helweg Dam, Rasmus Friis, Aleksander Moldt Haack, and Andreas Laustsen-Kiel. All who are or have been deeply involved in VenomAid! #medtech #snakebite #diagnostics

The diagnostic potential of non-invasive saliva sampling is truly impressive. https://lnkd.in/gUUvJBCd